Bicocca Open Archive

Logo unimib boa
INVERNIZZI, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.455
EU - Europa 8.652
AS - Asia 3.714
SA - Sud America 48
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 13
Totale 30.923
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.250
IT - Italia 2.313
SG - Singapore 1.364
IE - Irlanda 1.257
SE - Svezia 1.255
DE - Germania 1.233
CN - Cina 1.169
RU - Federazione Russa 989
HK - Hong Kong 625
GB - Regno Unito 520
UA - Ucraina 273
AT - Austria 229
CA - Canada 200
VN - Vietnam 155
FI - Finlandia 141
FR - Francia 126
TR - Turchia 99
IN - India 87
DK - Danimarca 81
NL - Olanda 69
ID - Indonesia 58
BE - Belgio 40
BR - Brasile 31
JP - Giappone 28
MY - Malesia 22
IR - Iran 19
CZ - Repubblica Ceca 18
PT - Portogallo 15
KR - Corea 14
PH - Filippine 14
ES - Italia 13
PL - Polonia 13
TW - Taiwan 12
IL - Israele 11
PK - Pakistan 11
RO - Romania 11
AU - Australia 10
CH - Svizzera 10
SK - Slovacchia (Repubblica Slovacca) 10
LT - Lituania 9
AR - Argentina 8
GR - Grecia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
DZ - Algeria 6
EU - Europa 6
SA - Arabia Saudita 6
SC - Seychelles 6
NO - Norvegia 5
GH - Ghana 4
MM - Myanmar 4
RS - Serbia 4
AL - Albania 3
BD - Bangladesh 3
EG - Egitto 3
NZ - Nuova Zelanda 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CL - Cile 2
CM - Camerun 2
EC - Ecuador 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MU - Mauritius 2
ZA - Sudafrica 2
ZW - Zimbabwe 2
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BZ - Belize 1
CO - Colombia 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
HU - Ungheria 1
IQ - Iraq 1
JM - Giamaica 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
ME - Montenegro 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PA - Panama 1
PY - Paraguay 1
Totale 30.923
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.833
Fairfield 1.778
Woodbridge 1.345
Dublin 1.206
Chandler 1.143
Singapore 1.132
Wilmington 1.023
Houston 977
Frankfurt am Main 943
Ashburn 925
Seattle 745
Milan 701
Cambridge 615
Hong Kong 611
New York 559
Dearborn 501
Princeton 468
Santa Clara 456
Jacksonville 371
Chicago 254
Lawrence 229
Vienna 224
Altamura 213
Nanjing 207
London 204
Shanghai 172
San Diego 136
Beijing 133
Boardman 106
Rome 102
Dong Ket 78
Andover 67
Lachine 62
Helsinki 61
Guangzhou 60
Toronto 59
Jakarta 57
Florence 55
Hangzhou 51
Los Angeles 51
Nanchang 51
Ottawa 44
Hebei 41
Brussels 38
Shenyang 38
Falls Church 37
Monza 36
Norwalk 36
Jinan 35
Bari 34
Changsha 34
Fremont 33
Lissone 31
Pune 31
Jiaxing 28
Tianjin 28
Washington 27
Bologna 25
Munich 23
San Mateo 23
Turin 23
Kunming 22
Dallas 21
Mountain View 21
Zhengzhou 20
Leawood 17
Taizhou 17
Brno 16
Edmonton 16
Kilburn 16
Ningbo 16
Padova 16
Penang 16
São Paulo 16
Lappeenranta 15
Genoa 14
Desio 13
Hefei 13
Groningen 12
Lisbon 12
Mumbai 12
Redmond 12
Garbagnate Milanese 11
Kiev 11
Kocaeli 11
Naples 11
Paris 11
Tappahannock 11
Bergamo 10
Catania 10
Como 10
New Bedfont 10
Providence 10
Romola 10
Ferrara 9
Huizen 9
Modena 9
Moscow 9
Napoli 9
Perugia 9
Totale 23.122
Salva come PNG Salva come JPEG
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 419
Validation of the Italian version of fisk fatigue severity score (FFSS) and PBC-40 357
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 343
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model 338
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 296
A short version of a HRQol questionnaire for Italian and Japanese patients with PBC 249
Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes 242
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 236
Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA 229
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 220
Better end points needed in primary sclerosing cholangitis trials 219
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 216
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 211
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload 208
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 206
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective 203
DCLK1, a putative novel stem cell marker in human cholangiocarcinoma 198
Dermatological Complications After Solid Organ Transplantation 192
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 191
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 190
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 189
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 188
It's as if PBC didn’t exist: The illness experience of women affected by primary biliary cirrhosis 187
Understanding short bowel syndrome: Current status and future perspectives 187
Precision medicine in primary biliary cholangitis 185
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 185
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 183
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 182
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 182
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 181
The X-factor in primary biliary cirrhosis: Monosomy X and xenobiotics 181
A second update on mapping the human genetic architecture of COVID-19 180
AISF position paper on liver disease and pregnancy 178
Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells 177
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 176
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 176
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 175
High rates of 30-day mortality in patients with cirrhosis and COVID-19 173
Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy 172
Risk stratification in primary sclerosing cholangitis 172
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion 170
The Seat of Life. What a Lesson from the Stigmatized Saints 170
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth 169
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 169
The challenges of primary biliary cholangitis: What is new and what needs to be done 169
Endocrinology and Metabolic Diseases (Including Diabetes) 168
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 167
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma 167
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 167
Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis 165
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 165
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development 165
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 163
Mapping the human genetic architecture of COVID-19 163
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 162
Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis 161
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 161
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth 161
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 161
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 161
“I Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism 158
Y chromosome loss in male patients with primary biliary cirrhosis 157
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation 157
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 156
New Therapeutic Targets in Autoimmune Cholangiopathies 156
Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis 156
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 156
Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism 155
MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response 155
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 154
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 154
Exploring the landscape of steatotic liver disease in the general US population 153
The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis 153
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 151
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth 151
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 150
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 149
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 147
Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma 145
Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice 145
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 144
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 144
Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis 143
Expert clinical management of autoimmune hepatitis in the real world 143
Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation 143
Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2−/− mice 142
Autoimmune liver diseases 139
COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy 139
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 139
Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases 138
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 137
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 137
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls 136
Prognostic models in primary biliary cholangitis 136
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C 136
Relationship between illness perception, anxiety, depression and fatigue in HCV patients 135
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: A multicentre international study 135
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study 133
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 133
Genetics and epigenetics of primary biliary cirrhosis 133
Totale 17.699
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.813
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.813
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.320 0 0 0 0 355 520 566 433 424 597 280 145
2020/20216.102 238 294 750 490 466 640 725 751 472 458 389 429
2021/20223.372 349 274 450 243 204 240 132 212 147 214 312 595
2022/20235.371 601 1.340 437 474 462 807 153 297 443 94 150 113
2023/20244.867 131 159 172 426 549 1.098 753 188 362 248 86 695
2024/20254.258 786 1.266 738 607 861 0 0 0 0 0 0 0
Totale 32.604